Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BI 767551 in Mild to Moderate COVID-19
NCT04822701Phase 3Terminated
- Sponsor
- Boehringer Ingelheim
- Start
- Apr 2021
- Primary completion
- Jul 2021
- Countries
- 2
01
Overview
A Phase 3 trial of lomtegovimab in coronavirus disease 2019 (COVID-19), sponsored by Boehringer Ingelheim. Started Apr 2021; status: terminated.
02
Drugs
lomtegovimab
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04822701.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04822701.